Expiration date: 08/2027

Dosage form

The powder is white to yellowish-brown in color.

Composition

Composition: per 1 g of powder

Active ingredient: alpha-glutamyl-tryptophan (Thymogen® sodium) (0.352 mg) in terms of alpha-glutamyl-tryptophan) 0.330 mg.

Excipients: sodium alginate, sodium carmellose, fructose, colloidal silicon dioxide.

Pharmacotherapeutic group

of tissue repair stimulator

Pharmacodynamics

It has a reparative, anti-inflammatory and enveloping effect in inflammatory and dystrophic diseases of the gastric mucosa.

It stimulates regeneration processes in case of their suppression in the presence of foci of atrophy of the gastric mucosa, preventing a reduction in the number of gastric glands. It helps to normalize the pH of the stomach (by increasing the number of gastric secretion glands in the preserved areas of the gastric mucosa), reduce the level of gastrin-17 in the blood, increase the ratio of pepsinogen I/ pepsinogen II levels, which is an indicator of the restoration of acid-forming and pepsin-forming functions and the weakening of pro-oncogenic processes associated with these disorders.

The drug has an anti-inflammatory effect, reducing the level of leukocyte infiltration of the gastric mucosa mainly due to eosinophilic granulocytes and macrophages.

It has a regulating effect on the reactions of cellular, humoral immunity and nonspecific resistance.

After eradication therapy (in people with Helicobacter pylori infection), treatment with the drug contributes to a more pronounced decrease in the titer of antihelicobacter antibodies, reducing the activity of the autoimmune component of inflammation of the gastric mucosa.

Pharmacokinetics

Alpha-glutamyl-tryptophan is released from the gel in the stomach and has a local effect on the gastric mucosa, the systemic blood flow reaches a small part of the administered dose.

Under the influence of peptidases, alpha-glutamyl-tryptophan is cleaved into

L-glutamic acid and L-tryptophan, which are used by the body in the synthesis of proteins and other biologically active compounds.

Indications

Comprehensive treatment of chronic atrophic gastritis.

Contraindications

Acute inflammatory diseases of the stomach and duodenum, oncological diseases, hypersensitivity to the components of the drug, sucrose/isomaltase deficiency, glucose-galactose malabsorption, children under 18 years of age, pregnancy, breastfeeding. Before prescribing the drug, fructose tolerance should be established. It is contraindicated in patients with hereditary fructose intolerance.

Precautions for use: Not required.

Use during pregnancy and breastfeeding:

The use of the drug during pregnancy and during breastfeeding is contraindicated.

Method of administration and dosage

Inside. The drug is taken orally in the form of a gel 2 times a day on an empty stomach (in the morning 20-30 minutes before meals and in the evening before bedtime, no earlier than an hour after meals). Before use, mix a single dose of 3 g of powder (1 teaspoon) for about 3-5 minutes in 50 ml (1/4 cup) of hot, but not boiling water until a gel of homogeneous consistency is obtained. The gel is prepared immediately before use. For the convenience of mixing, it is recommended to add water to the powder, and not vice versa.

The course of treatment is 28 days.

In case of atrophic gastritis associated with Helicobacter pylori, the drug should be used after a course of eradication therapy.

If the dynamics of treatment is positive, it is possible to repeat the course after 2 weeks according to the doctor's prescription.

Side effects

Classification of adverse reactions by frequency of development (number of reported cases/number of patients): very common (≥1/10), common (≥1/100, < 1/10), infrequent (≥1/1000, <1/100), frequency unknown (side effects from post-marketing experience; frequency cannot be estimated based on available data).

Disorders of the immune system

The frequency is unknown: allergic reaction, hypersensitivity to the components of the drug.

Disorders of the gastrointestinal tract

Frequency unknown: relaxation of the stool.

If any side effects occur, stop taking the drug and consult a doctor.

Overdose

Overdose cases are not known.

Drug interaction

It has not been studied.

Special instructions

Description of the actions of the doctor or patient when skipping one or more doses:

If one or more doses are missed, treatment is not stopped, it is recommended to extend the course of treatment by the number of missed days of admission.

Influence on the ability to drive vehicles, mechanisms:

The drug does not affect the ability to drive vehicles, work with moving mechanisms and engage in other potentially dangerous activities that require increased concentration and speed of psychomotor reactions.

Storage temperature

from 2℃ to 25℃